Nextech Invest — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Albert Lehr(Executive Officer, Director)Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)Alex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)
Co-investorsTorrey Pines Investment
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)Alan Fuhrman(Executive Officer)
BoardRobert More(Director)Nina Kjellson(Director)in
Co-investorsAlta PartnersBioBritCanaan Partners
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)
Co-investorsGV (Google Ventures)Taiho Ventures, LLCAlexandria
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.